Bulletin
Investor Alert

Market Pulse Archives

July 28, 2021, 8:51 a.m. EDT

Europe buys 220,000 doses of Vir, GSK's experimental COVID-19 treatment

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Vir Biotechnology Inc. (VIR)
  • X
    GlaxoSmithKline PLC ADR (GSK)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

Shares of Vir Biotechnology Inc. /zigman2/quotes/214486077/composite VIR +3.67% gained 1.9% in premarket trading on Wednesday after the company and GlaxoSmithKline /zigman2/quotes/209463850/composite GSK -0.46% said the European Commission purchased 220,00 doses of their investigational COVID-19 antibody treatment. The therapy is a single-dose monoclonal antibody that is being tested as a treatment to ward off severe disease in some high-risk COVID-19 patients. The European Medicines Agency is currently reviewing the companies' application for sotrovimab. (Sotrovimab received emergency authorization in the U.S. in May, and it has also been authorized in Qatar, Singapore, and the United Arab Emirates.) Vir's stock is up 36.0% for the year, while the S&P 500 /zigman2/quotes/210599714/realtime SPX -0.91% has gained 17.2%.

/zigman2/quotes/214486077/composite
US : U.S.: Nasdaq
$ 54.54
+1.93 +3.67%
Volume: 1.02M
Sept. 17, 2021 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$7.12 billion
Rev. per Employee
$233,541
loading...
/zigman2/quotes/209463850/composite
US : U.S.: NYSE
$ 38.93
-0.18 -0.46%
Volume: 3.46M
Sept. 17, 2021 4:00p
P/E Ratio
16.56
Dividend Yield
5.14%
Market Cap
$88.73 billion
Rev. per Employee
$464,855
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
4,432.99
-40.76 -0.91%
Volume: 3.79B
Sept. 17, 2021 5:25p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.